COVID-19 transmission graph

Coronavirus: WHO declares COVID 19 a pandemic. Prevention | FAQs | COVID-19 portal

URGENT:COVID prophylaxis | Vitamin D | Latest research | NIH | CDC | Worldometer

NB:Did you know one coronavirus patient can infect 59,000 others if nothing is done? Dietary cholesterol may not raise cardiovascular risk! Ketogenic diet

Trifluridine/Tipracil

From WikiMD
Jump to navigation Jump to search

Information about Trifluridine/Tipracil

Trifluridine/tipiracil is the combination of an antineoplastic pyrimidine analogue (trifluridine) with an inhibitor of its metabolism (tipiracil) that is used in the therapy of refractory, metastatic colorectal cancer. 

Liver safety of Trifluridine/Tipracil

Trifluridine/tipiracil is associated with a low rate of transient serum enzyme elevations during therapy, but has not been implicated in cases of clinically apparent acute liver injury with jaundice. 

Mechanism of action of Trifluridine/Tipracil

Trifluridine (trye flure' i deen)/tipiracil (tye pir’ a sil) combines an antineoplastic pyrimidine analogue (2-deoxy-5-trifluoromethyl uridine) with a thymidine phosphorylase inhibitor that blocks its rapid metabolism, thus increasing the bioavailability of trifluridine.  Trifluridine is absorbed orally and converted intracellularly to a triphosphate which becomes incorporated into DNA causing inhibition of DNA synthesis, a decrease in cellular growth and proliferation and triggering apoptosis.  Trifluridine triphosphate is metabolized by thymidine phosphorylase which is inhibited by tipiracil, thus providing a longer half-life and increased intracellular concentrations of active phosphorylated trifluridine.  Trifluridine/tipiracil was shown to have potent activity in vitro in cellular and in vivo in animal models of colon cancer.  In clinical trials, this combination led to prolongation of progression-free as well as overall survival in patients with previously treated, refractory metastatic colorectal cancer

FDA approval information for Trifluridine/Tipracil

Trifluridine/tipiracil was approved for use in the United States in 2015 and is available in tablets of 15 mg/14 mg and 20 mg/19 mg under the commercial name Lonsurf. 

Clinical use of Trifluridine/Tipracil

Current indications are for refractory, metastatic colorectal cancer after previous treatment with other agents.  The recommended dose regimen is 35 mg/m2(based upon the trifluridine component) orally twice daily on days 1 through 5 and days 8 through 12 of each 28-day cycle. 

Side effects of Trifluridine/Tipracil

Common side effects include bone marrow suppression, weakness, fatigue, nausea, anorexia, diarrhea, abdominal pain and fever.  Less common, but potentially severe adverse events include severe myelosuppression, febrile neutropenia, infections, sepsis and embryo-fetal toxicity.

 


The article on Trifluridine/Tipracil is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more

Apple bitten.svg

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information.

Join us: Do not trust amateurs with your life! Join us in this effort!

W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Trifluridine/Tipracil">Trifluridine/Tipracil</a>

  • Individual results may vary for weight loss from our sponsors.